title: Effects of linoleic and gamma-linolenic acids (efamol evening primrose oil) on fatty acid-binding proteins of rat liver.
abstract: We have studied the effects of Efamol evening primrose oil (EPO) on fatty acid-binding proteins (L-FABP) of rat liver. EPO contains 72% cis-linoleic acid and 9% cis-gamma linolenic acid. EPO has been clinically used for treatment of a number of diseases in humans and animals. EPO is also known to lower cholesterol level in humans and animals. Feeding of an EPO supplemented diet to rats (n = 9) for 2 months decreases the oleate binding capacity of purified L-FABP of rat liver whereas the palmitate binding activity was increased by 38%. However, EPO feeding did not alter the L-FABP concentrations significantly as measured by using the fluorescence fatty acid probe, dansylamino undecanoic acid. Endogenous fatty acid analysis of L-FABPs revealed significant qualitative and quantitative changes in fatty acid pattern after EPO feeding. EPO feeding decreased the endogenous palmitate level by 53% and oleate level by 64% in L-FABPs and also EPO feeding decreased the total endogenous fatty acid content from 62 nanomole per mg of protein to 42 nanomole per mg of L-FABP (n = 3).
authors.affiliation: Efamol Research Institute, Kentville, Nova Scotia, Canada.
authors.forename: A K
authors.initials: AK
authors.lastname: Dutta-Roy
authors.forename: A C
authors.initials: AC
authors.lastname: Demarco
authors.forename: S K
authors.initials: SK
authors.lastname: Raha
authors.forename: J
authors.initials: J
authors.lastname: Shay
authors.forename: M
authors.initials: M
authors.lastname: Garvey
authors.forename: D F
authors.initials: DF
authors.lastname: Horrobin
mesh_terms: D000818:Animals; D002352:Carrier Proteins / Q000378:metabolism*; D002788:Cholesterol Esters / Q000378:metabolism; D004435:Eating; D000071438:Fatty Acid-Binding Protein 7; D050556:Fatty Acid-Binding Proteins; D005228:Fatty Acids, Essential / Q000494:pharmacology*; D005260:Female; D006801:Humans; D000960:Hypolipidemic Agents / Q000494:pharmacology; D019787:Linoleic Acid; D008041:Linoleic Acids / Q000494:pharmacology*; D008042:Linolenic Acids / Q000494:pharmacology*; D008099:Liver / Q000187:drug effects / Q000378:metabolism*; D009363:Neoplasm Proteins; D009419:Nerve Tissue Proteins; D031665:Oenothera biennis; D010743:Phospholipids / Q000378:metabolism; D010938:Plant Oils; D051381:Rats; D011919:Rats, Inbred Strains; D014280:Triglycerides / Q000378:metabolism; D025521:Tumor Suppressor Proteins; D017965:gamma-Linolenic Acid
chemical_list: D002352:Carrier Proteins; D002788:Cholesterol Esters; C493319:FABP1 protein, human; C107608:FABP7 protein, human; C493320:Fabp1 protein, mouse; C493321:Fabp1 protein, rat; C490174:Fabp7 protein, rat; D000071438:Fatty Acid-Binding Protein 7; D050556:Fatty Acid-Binding Proteins; D005228:Fatty Acids, Essential; D000960:Hypolipidemic Agents; D008041:Linoleic Acids; D008042:Linolenic Acids; D009363:Neoplasm Proteins; D009419:Nerve Tissue Proteins; D010743:Phospholipids; D010938:Plant Oils; D014280:Triglycerides; D025521:Tumor Suppressor Proteins; C028498:evening primrose oil; D017965:gamma-Linolenic Acid; D019787:Linoleic Acid